treatment experiment, survival at 14 days was lower in treated compared with control animals, and there was more infiltration, more severe necrosis, and more T-cell infiltration, but the NK cell activity did not differ significantly. In a third experiment similar to the late experiment described above but involving infected athymic nude mice, we confirmed the lack of effect of late in vivo administration of IL-2 on outcome.
Conclusions IL-2 has the capacity to limit CB3 myocarditis by enhancing NK cell activity in the acute viremic stage, resulting in a reduction of cardiac pathology. However, in the subacute aviremic stage, in contrast, IL-2 exacerbates the course and severity of the disease by increasing the number of T cells infiltrating the myocardium. That is, IL-2 has differential effects on acute CB3 myocarditis. IL-2 is beneficial if treatment is given early but not later in murine CB3 myocarditis. (Circulation. 1994;89:2836-2842.) Key Words * myocarditis * coxsackievirus B3 * T cells * interleukin-2 * cytokines * natural killer cells It has been established that coxsackieviruses are the predominant cause of viral myocarditis in humans.1-3 Virus-induced immunologic mechanisms have been implicated in the pathogenesis of human myocarditis.4 Indeed, we have previously demonstrated experimentally that T cells play a role in the development of coxsackievirus B3 (CB3) myocarditis. [6] [7] [8] Interleukin-2 (IL-2), a T-cell-derived cytokine that stimulates the growth of the T cell,9'10 has been shown to play a significant role in supporting the growth of natural killer (NK) cellsll-13; it may also stimulate the cytotoxic activity of T-lymphocytes. 13-'5 Increased NK cell activity has been shown to occur early during the course of infections with various viruses. [16] [17] [18] Many of these viral infections induce interferon, which mediates antiviral effects; interferon also activates NK cells.18 Numerous studies also have demon-strated that the in vitro incubation of lymphocytes with IL-2 leads to the generation of activated T cells that can lyse a wide variety of tumor cells.13-1 'Furthermore, the direct in vivo administration of IL-2 has been shown to generate cytotoxic T cells in various tissues. '9-22 In the present study, to clarify the function of IL-2 during the development of myocarditis and to reconfirm the underlying biphasic disease process in the pathogenesis of the condition, we studied the clinical course, cardiac pathology, myocardial lymphocyte subsets, and NK cell activity in murine CB3 myocarditis with and without IL-2 treatment.
Methods

Virus Preparation
The method used was similar to that described in previous reports.6-8 In brief, CB3 (Nancy strain, American Type Culture Collection) was used; the virus stock was prepared in cultures of VERO (African green monkey kidney) cells in Eagle's minimum essential medium (EMEM). Virus suspensions were centrifuged after the cytopathic effect had developed. Virus stock had a titer of more than 109 plaque-forming units (PFU) per 0.1 mL, determined by plaque assay. The suspension was stored at -80°C until use.
They were maintained in laminar-flow isolation rooms throughout the study period. It has been reported that BALB/c BYJ mice, which belong to the Andervont family, develop CD4+ cell-and IL-2-dependent autoimmunity. 23 Recombinant human IL-2 was kindly supplied by Shionogi Pharmaceutical Co, Ltd, Osaka, Japan. IL-2 was administered subcutaneously daily at rotated sites, the dose being 5 x 104 U per mouse per day. We selected this dose because previous reports have demonstrated it to be both well tolerated and effective in animals. [19] [20] [21] [22] Mice in the untreated groups were injected subcutaneously with 0.2 mL of saline during the treatment period.
Experiment 1
This experiment (early protocol) was carried out to determine the effects of IL-2 on acute viremic CB3 myocarditis. Sixty mice were randomized to group 1 (n=30, no IL-2 treatment) or to group 2 (n=30, treatment with IL-2). Starting simultaneously with the virus inoculation, treatment was administered daily for 7 days. The mice were observed daily, and necropsy was performed immediately on mice that were found dead. Mice surviving until the end of the treatment period were killed by bleeding from the retro-orbital plexus and then were necropsied; the spleens were processed for NK cell activity study and the hearts for pathological and virologic studies. Other organs were processed for pathological study.
Additional groups of uninfected mice treated for 7 days with saline (n=3) or IL-2 (5 x 104 U per mouse per day) (n=3) also were prepared; the spleens were processed for the assay of NK cell activity and other organs for pathological study.
Experiment 2
This experiment (late protocol) was carried out to determine the effects of IL-2 on subacute aviremic CB3 myocarditis. Altogether, 98 mice were inoculated with virus and randomized to the treatment or control groups. Before treatment began, 5 mice in each group were killed and processed for pathological study to confirm group homogeneity (data not presented). At Analysis of splenic NK cell activity and the myocardial immunohistological examination were performed on day 10 in subsampled mice in both groups (each n=4). Thus, the numbers of the subsampled mice were subtracted from those in the mortality study in both groups.
Experiment 3
We investigated the changes of cardiac pathology in CB3-infected nude mice (BALB/c-nu/nu) with or without IL-2 treatment (nude mouse protocol) in parallel with experiment 2. Twenty-one 4-week-old, male, athymic nude mice were inoculated intraperitoneally with 6x 105 PFU of CB3 on day 0. Sixteen mice that survived for 7 days after the virus inoculation were divided into groups and received the same treatment as in experiment 2 (starting on day 7); they served as the controls for the in vivo administration of IL-2 in T-cell-depleted mice. On day 14, the mice were killed, and their organs were processed for pathological study.
NK Cell Assay NK cell assay was performed on day 7 in experiment 1 and on day 10 
Spleen Cells
Spleens were mechanically dissociated with a 23-gauge needle in RPMI-1640 medium. The cell suspension was collected, and erythrocytes were lysed with 0.83% NH4Cl in Tris buffer (pH 7.2) followed by two washes with RPMI-1640 medium. To remove macrophages, spleen cells were incubated in RPMI-1640 medium with 10% silica suspension and 10% autologous fresh serum for 45 minutes at 37°C. The cell suspensions were carefully overlayered on Ficoll-Paque (Pharmacia, Inc) and then centrifuged at 3000 rpm for 30 minutes. The cells remaining on the interface were collected, washed twice, and resuspended in RPMI-1640 medium with 10% FCS.
Cytotoxicity Assay
Target cells (1 x 106) were labeled with 3.7 MBq 5`Cr for 60 minutes at 37°C in 5% CO2. Labeled target cells were washed three times, and 1 x 104 cells/well were added to flat-bottomed, 96-well microtiter plates (Corning) together with effector cells at effector-target cell (ET) ratios of 12.5:1, 25:1, and 50:1.
After 4 hours of incubation at 37°C, the supernatant was collected using a supernatant-collecting system made by Skatron, and the amount of 5`Cr released into the supernatant fluid was measured. The percent cytotoxicity was calculated with the formula
where E is the counts per minute (cpm) released in the presence of effector cells, S is the cpm released from target cells incubated alone in medium, and M is the cpm released from target cells incubated alone followed by 0.1N HCI treatment. All experimental points shown in the text are the mean of duplicate or triplicate samples.
Pathologic Study
Tissues (heart, thymus, spleen, lung, liver, kidney, psoas muscle, and pancreas) were processed by standard methods, embedded in paraffin, cut into 5-,um-thick sections, and stained with hematoxylin and eosin. Myocardial sections were graded by two of the authors, who were blinded to the respective treatment groups for the severity of infiltration and necrosis of the ventricles. The mean values are cited. The pathological criteria for grading the severity of infiltration and necrosis were grade 1 (mild), one or two small foci; grade 2 (slight), several small foci; grade 3 (moderate), multiple small foci or several large foci; and grade 4 (severe), multiple large 8h-EEE--_;t-ER~~~~~~~~~"--10 minutes, the resultant supernatants were inoculated into VERO cells, and plaque assays were performed. [6] [7] [8] Statistics ANOVA for multiple sample comparisons (Bonferroni) was used to evaluate differences in pathological scores, NK cell activity, immunohistological data, and myocardial virus titers. Kaplan-Meier plots were made of the survival data,24 and differences between the control and treatment survival curves were evaluated by the Mantel-Cox log-rank test.25 y 2 analysis with Yates' correction was used to compare the incidence of congestive failure by gross appearance. A probability value of <.05 was considered statistically significant.
Results
Infection with CB3 produced a similar pathological picture to that reported previously.6 8 In brief, 3 days after the virus inoculation, the mice appeared ill; some developed coat ruffling, weakness, and irritability. In gross appearance, the myocardium had pale yellow patches that correlated with the infiltration, necrosis, and calcification seen microscopically. After day 7, myocardial necrosis and inflammatory cell infiltrations were more extensive (Fig 1) . Pleural effusion, ascites, and congestion of the lungs and liver were noted thereafter.6-8 percentage of T-series lymphocytes in the diseased myocardium on day 10 in IL-2-treated mice was significantly higher than that in IL-2-untreated mice in experiment 2. This finding indicated that the in vivo administration of IL-2 possibly increased the accumulation of T lymphocytes in the inflammed myocardium in subacute (immune phase) CB3 myocarditis. (See Table 2 .) Nude Mouse Study (Experiment 3)
The survival rates of IL-2-treated and untreated groups did not differ significantly. The pathological study showed that the severity of myocarditis was very mild in both groups of mice (IL-2 treated and untreated) and that there were no significant differences in the pathological scores of the IL-2-treated and untreated groups; these results strongly indicated that IL-2, administered in vivo, acts via T lymphocytes. (See Table 3 .)
Discussion
This study clearly demonstrates that IL-2 has the capacity to limit myocardial virus replication by enhancing NK cell activity in the acute, viremic stage of CB3 myocarditis, resulting in a reduction of cardiac pathology; however, in the later stage, in contrast, IL-2 exacerbated the course and severity of the disease by increasing the number of T cells infiltrating the myocardium. In other words, IL-2 has differential effects on acute CB3 myocarditis. This finding may be of great This study was conducted to determine the effects of IL-2 administration on T-celI-depleted mice. For this study, we used the protocol used in experiment 2. There was no significant difference between IL-2-treated and untreated groups in cardiac pathological scores. For myocardial lesions, cellular infiltration and myocardial necrosis were scored blindly, on a scale of 1 + to 4+ in terms of severity.
value in increasing our understanding of the pathogenesis of this condition.
The murine model of CB3-induced myocarditis has been shown to closely mimic the pathology of human myocarditis.1' 3The myocardial lesions are focal, consisting of necrotic myocytes within an infiltration of mononuclear and polymorphonuclear cells. Most animal studies suggest that the heart lesions result not only from virus-induced direct myocytolysis but also from immune responses to virus-infected cells in the heart.26-29 A cell-mediated reaction to virus-induced neoantigens in heart tissues of infected mice has been strongly implicated in the pathogenesis of CB3-induced myocarditis,26-29 and cytotoxic T lymphocytes have been proposed to be the major effector cells involved in the immunopathology. [6] [7] [8] [26] [27] [28] [29] In experiment 1, there was a correlation between virus titers and NK cell activity, suggesting that a primary role of NK cells in this model is to reduce CB3 titers in heart tissues early in the course of infection. Presumably, NK cell activity also reduces some of the subsequent pathology. Godney and Gauntt3031 also found evidence that NK cells played a role in limiting virus replication in the heart tissues of CB3-inoculated mice, which in turn ameliorated the severity of the myocarditis. CB3 infection per se stimulated NK cell activity, which was further stimulated by IL-2 administration.
Experiment 2 provides evidence that the in vivo administration of IL-2 increased the number of T cells infiltrating the myocardium, thus exacerbating the severity of myocardial damage. In vivo-stimulated T cells might damage both CB3-induced inflamed and intact myocytes. In vivo-generated T cells have been shown to kill fresh autologous, syngeneic, and allogeneic tumor cells (probably by the recognition of tumor antigenecity). '9-22 Our findings demonstrated that the in vivostimulated T cells derived from the aviremic stage, when immune or autoimmune mechanisms may operate in the development of myocarditis, increased the severity of myocarditis. Stimulated T cells induced by IL-2 administration that might include a major population of cytotoxic T cells caused the severe myocardial damage. Regarding the survival rate, especially in experiment 2, it is conceivable that, when congestive heart failure caused by severe myocardial damage developed, IL-2 side effects, that is, peripheral and pulmonary edema, hypotension, and tachycardia,32 may have been superimposed.
In experiment 3, the lack of effect of IL-2 administration on nude mice was confirmed. Estrin 
